Dyne Therapeutics (DYN) Non-Current Debt (2020 - 2026)
Dyne Therapeutics (DYN) posted quarterly Non-Current Debt of $199.3 million for Q2 2026, up 101.72% year-over-year from $98.8 million in Q2 2025, and up 33.44% quarter-over-quarter from $149.4 million in Q1 2026.
Dyne Therapeutics (DYN) Non-Current Debt (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Non-Current Debt for 3 consecutive years, with $199.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt rose 101.72% year-over-year to $199.3 million; the TTM figure through Jun 2026 stood at $199.3 million (up 101.72% YoY), while the FY2025 annual figure was $148.9 million, changed N/A from the prior year.
- Non-Current Debt climbed to $199.3 million in Q2 2026 per DYN's latest filing, from $149.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $199.3 million in Q2 2026 and bottomed at $98.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 199.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199.33 Mn |
| Mar 31, 2026 | 149.38 Mn |
| Dec 31, 2025 | 148.92 Mn |
| Sep 30, 2025 | 99.15 Mn |
| Jun 30, 2025 | 98.81 Mn |
| Sep 30, 2020 | 9.94 Mn |